PCR Enzyme Patent Dispute Leads To Overbilling Charges; DoJ Takes A Pass
This article was originally published in The Gray Sheet
Executive Summary
The Department of Justice says it will not intervene in a Promega civil action alleging that Roche overbilled the government for Taq enzyme-related products, and seeking redress under the False Claims Act